Irish Journal of Medical Science

, Volume 183, Issue 1, pp 47–52 | Cite as

Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis

  • J. J. Brady
  • R. K. Crowley
  • B. F. Murray
  • M. T. Kilbane
  • M. O’Keane
  • M. J. McKenna
Original Article



Tartrate-resistant acid phosphatase isoform 5b (TRACP5b) is a serum bone resorption marker. Our aim was to investigate its utility in monitoring metabolic bone disease.


Serum TRACP5b, C-terminal cross-linking telopeptide of type I collagen, urine N-terminal cross-linking telopeptide of type I collagen and free deoxypyridinoline were measured pre- and post-treatment with a parathyroid hormone analogue [PTH (1–34)] (n = 14) or a bisphosphonate (N-BP) (n = 8). TRACP5b, bone alkaline phosphatase (bone ALP), 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in 100 osteoporosis patients on prolonged bisphosphonate therapy.


Changes in TRACP5b were smaller in magnitude but mimicked those of other bone resorption markers. Absolute changes in TRACP5b and the other resorption markers correlated significantly (p < 0.001). In patients on long-term bisphosphonates, TRACP5b and bone ALP levels were not suppressed. Vitamin D status was consistent with the level of supplementation.


TRACP5b has limited utility as a single marker of metabolic bone disease treatment.


TRACP5b Bisphosphonate Bone turnover markers PTH Vitamin D 


  1. 1.
    Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93(8):2948–2952. Doi: 10.1210/jc.2007-2803 Google Scholar
  2. 2.
    Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22(5):346–350. doi: 10.1097/BOT.0b013e318172841c Google Scholar
  3. 3.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267–2294. doi: 10.1002/jbmr.253 PubMedCrossRefGoogle Scholar
  4. 4.
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613–620. doi: 10.1359/jbmr.2000.15.4.613 PubMedCrossRefGoogle Scholar
  5. 5.
    Diab T, Condon KW, Burr DB, Vashishth D (2006) Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone 38(3):427–431. doi: 10.1016/j.bone.2005.09.002 PubMedCrossRefGoogle Scholar
  6. 6.
    Szulc P, Delmas PD (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int 19(12):1683–1704. doi: 10.1007/s00198-008-0660-9 PubMedCrossRefGoogle Scholar
  7. 7.
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–S17Google Scholar
  8. 8.
    Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47(4):694–702PubMedGoogle Scholar
  9. 9.
    Terreni A, Pezzati P (2012) Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab 9(2):80–84PubMedCentralPubMedGoogle Scholar
  10. 10.
    Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18(5):681–685. doi: 10.1007/s00198-006-0286-8 PubMedCrossRefGoogle Scholar
  11. 11.
    Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34(1):187–194. pii:S875632820300379XGoogle Scholar
  12. 12.
    Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, O’Farrelly C, Hegarty JE (2009) Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 7(8):894–899. doi: 10.1016/j.cgh.2009.01.011 Google Scholar
  13. 13.
    Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, Hagan R, Duggan M, Jordan S, McKenna M, Hutchinson M, Tubridy N (2011) Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 82(3):317–322. doi: 10.1136/jnnp.2010.220988 PubMedCrossRefGoogle Scholar
  14. 14.
    Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13(7):1124–1133. doi: 10.1359/jbmr.1998.13.7.1124 PubMedCrossRefGoogle Scholar
  15. 15.
    Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, Vuori I, Vaananen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20(10):1804–1812. doi: 10.1359/JBMR.050403 PubMedCrossRefGoogle Scholar
  16. 16.
    Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45(6):1053–1058. doi: 10.1016/j.bone.2009.07.091 Google Scholar
  17. 17.
    Plotkin H, Gundberg C, Mitnick M, Stewart AF (1998) Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1–36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83(8):2786–2791PubMedGoogle Scholar
  18. 18.
    Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40(6):1447–1452. doi: 10.1016/j.bone.2006.09.008 Google Scholar
  19. 19.
    Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3(Suppl 3):S131–139. doi: 10.2215/CJN.04151206 Google Scholar
  20. 20.
    Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30(6):886–890 pii:S8756328202007287PubMedCrossRefGoogle Scholar
  21. 21.
    Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine (2011) Dietary reference intakes for calcium and vitamin D. The National Academies Press, USAGoogle Scholar
  22. 22.
    Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96(1):53–58. doi: 10.1210/jc.2010-2704 PubMedCrossRefGoogle Scholar
  23. 23.
    McKenna MJ, Murray BF (2013) Vitamin D dose response is underestimated by Endocrine Society’s Clinical Practice Guideline. Endocrine Connections 2(2):87–95. doi: 10.1530/ec-13-0008 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2013

Authors and Affiliations

  • J. J. Brady
    • 1
  • R. K. Crowley
    • 2
  • B. F. Murray
    • 1
  • M. T. Kilbane
    • 1
  • M. O’Keane
    • 1
  • M. J. McKenna
    • 1
    • 2
    • 3
  1. 1.Metabolism LaboratorySt. Vincent’s University HospitalDublinIreland
  2. 2.St. Michael’s Hospital, Dún LaoghaireDublinIreland
  3. 3.School of Medicine and Medical SciencesUniversity College DublinDublinIreland

Personalised recommendations